These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 21106949

  • 1. Adenosine derived from ADP can contribute to inhibition of platelet aggregation in the presence of a P2Y12 antagonist.
    Iyú D, Glenn JR, White AE, Fox SC, Heptinstall S.
    Arterioscler Thromb Vasc Biol; 2011 Feb; 31(2):416-22. PubMed ID: 21106949
    [Abstract] [Full Text] [Related]

  • 2. Mode of action of P2Y(12 ) antagonists as inhibitors of platelet function.
    Iyú D, Glenn JR, White AE, Fox SC, van Giezen H, Nylander S, Heptinstall S.
    Thromb Haemost; 2011 Jan; 105(1):96-106. PubMed ID: 20941457
    [Abstract] [Full Text] [Related]

  • 3. P2Y₁₂ and EP3 antagonists promote the inhibitory effects of natural modulators of platelet aggregation that act via cAMP.
    Iyú D, Glenn JR, White AE, Fox SC, Dovlatova N, Heptinstall S.
    Platelets; 2011 Jan; 22(7):504-15. PubMed ID: 21591981
    [Abstract] [Full Text] [Related]

  • 4. Incomplete reversibility of platelet inhibition following prolonged exposure to ticagrelor.
    Gerrits AJ, Jakubowski JA, Sugidachi A, Michelson AD, Frelinger AL.
    J Thromb Haemost; 2017 May; 15(5):858-867. PubMed ID: 28092426
    [Abstract] [Full Text] [Related]

  • 5. The P2Y(12) antagonists, 2MeSAMP and cangrelor, inhibit platelet activation through P2Y(12)/G(i)-dependent mechanism.
    Xiang B, Zhang G, Ren H, Sunkara M, Morris AJ, Gartner TK, Smyth SS, Li Z.
    PLoS One; 2012 May; 7(12):e51037. PubMed ID: 23236426
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. P2Y12 platelet receptors: importance in percutaneous coronary intervention.
    Falcão FJ, Carvalho L, Chan M, Alves CM, Carvalho AC, Caixeta AM.
    Arq Bras Cardiol; 2013 Sep; 101(3):277-82. PubMed ID: 23917456
    [Abstract] [Full Text] [Related]

  • 9. 'VASPFix' for measurement of VASP phosphorylation in platelets and for monitoring effects of P2Y12 antagonists.
    Glenn JR, Dovlatova N, White AE, Dhillon K, Heptinstall S, Fox SC.
    Thromb Haemost; 2014 Mar 03; 111(3):539-48. PubMed ID: 24258486
    [Abstract] [Full Text] [Related]

  • 10. Comparison of antiplatelet effects of prasugrel and ticagrelor in cynomolgus monkeys by an ELISA-based VASP phosphorylation assay and platelet aggregation.
    Tomizawa A, Ohno K, Jakubowski JA, Mizuno M, Sugidachi A.
    Thromb Haemost; 2013 Oct 03; 110(4):769-76. PubMed ID: 23903326
    [Abstract] [Full Text] [Related]

  • 11. The active metabolite of prasugrel effectively blocks the platelet P2Y12 receptor and inhibits procoagulant and pro-inflammatory platelet responses.
    Judge HM, Buckland RJ, Sugidachi A, Jakubowski JA, Storey RF.
    Platelets; 2008 Mar 03; 19(2):125-33. PubMed ID: 18297550
    [Abstract] [Full Text] [Related]

  • 12. P2Y12 antagonist ticagrelor inhibits the release of procoagulant extracellular vesicles from activated platelets.
    Gasecka A, Nieuwland R, van der Pol E, Hajji N, Ćwiek A, Pluta K, Konwerski M, Filipiak KJ.
    Cardiol J; 2019 Mar 03; 26(6):782-789. PubMed ID: 29671861
    [Abstract] [Full Text] [Related]

  • 13. The platelet P2Y₁₂ receptor for adenosine diphosphate: congenital and drug-induced defects.
    Cattaneo M.
    Blood; 2011 Feb 17; 117(7):2102-12. PubMed ID: 20966167
    [Abstract] [Full Text] [Related]

  • 14. Pharmacodynamic effects during the transition between cangrelor and ticagrelor.
    Schneider DJ, Agarwal Z, Seecheran N, Keating FK, Gogo P.
    JACC Cardiovasc Interv; 2014 Apr 17; 7(4):435-42. PubMed ID: 24656538
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Onset of optimal P2Y12-ADP receptor blockade after ticagrelor and prasugrel intake in Non-ST elevation acute coronary syndrome.
    Bonello L, Laine M, Camoin-Jau L, Noirot F, Guieu R, Dignat-George F, Paganelli F, Frere C.
    Thromb Haemost; 2015 Oct 17; 114(4):702-7. PubMed ID: 26311415
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Pharmacodynamic effects of cangrelor on platelet P2Y12 receptor-mediated signaling in prasugrel-treated patients.
    Rollini F, Franchi F, Tello-Montoliu A, Patel R, Darlington A, Ferreiro JL, Cho JR, Muñiz-Lozano A, Desai B, Zenni MM, Guzman LA, Bass TA, Angiolillo DJ.
    JACC Cardiovasc Interv; 2014 Apr 17; 7(4):426-34. PubMed ID: 24630878
    [Abstract] [Full Text] [Related]

  • 20. Curcumin by activation of adenosine A2A receptor stimulates protein kinase a and potentiates inhibitory effect of cangrelor on platelets.
    Rukoyatkina N, Shpakova V, Bogoutdinova A, Kharazova A, Mindukshev I, Gambaryan S.
    Biochem Biophys Res Commun; 2022 Jan 01; 586():20-26. PubMed ID: 34823218
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.